These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 31645880)
41. JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. Bose P; Verstovsek S Hemasphere; 2020 Aug; 4(4):e424. PubMed ID: 32903304 [TBL] [Abstract][Full Text] [Related]
42. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Masarova L; Bose P; Pemmaraju N; Daver NG; Zhou L; Pierce S; Sasaki K; Kantarjian HM; Estrov Z; Verstovsek S Cancer; 2020 Oct; 126(19):4322-4331. PubMed ID: 32697338 [TBL] [Abstract][Full Text] [Related]
43. Management of challenging myelofibrosis after JAK inhibitor failure and/or progression. Scherber RM; Mesa RA Blood Rev; 2020 Jul; 42():100716. PubMed ID: 32593470 [TBL] [Abstract][Full Text] [Related]
44. The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis. Palmer J; Mesa R Ther Adv Hematol; 2020; 11():2040620720925201. PubMed ID: 32477483 [TBL] [Abstract][Full Text] [Related]
45. Modern management of splenomegaly in patients with myelofibrosis. Tremblay D; Schwartz M; Bakst R; Patel R; Schiano T; Kremyanskaya M; Hoffman R; Mascarenhas J Ann Hematol; 2020 Jul; 99(7):1441-1451. PubMed ID: 32417942 [TBL] [Abstract][Full Text] [Related]
46. Management of Myelofibrosis: from Diagnosis to New Target Therapies. Iurlo A; Cattaneo D; Bucelli C Curr Treat Options Oncol; 2020 Apr; 21(6):46. PubMed ID: 32350623 [TBL] [Abstract][Full Text] [Related]
48. Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms. Zhou S; Tremblay D; Hoffman R; Kremyanskaya M; Najfeld V; Li L; Moshier E; Mascarenhas J Acta Haematol; 2021; 144(1):48-57. PubMed ID: 32160610 [TBL] [Abstract][Full Text] [Related]
49. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Jourdan E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Shen J; Berry T; Brownstein C; Mesa RA Am J Hematol; 2020 Jun; 95(6):594-603. PubMed ID: 32129512 [TBL] [Abstract][Full Text] [Related]
50. Stem cell transplant for the treatment of myelofibrosis. Mannelli L; Guglielmelli P; Vannucchi AM Expert Rev Hematol; 2020 Apr; 13(4):363-374. PubMed ID: 32077336 [No Abstract] [Full Text] [Related]
51. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis. Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387 [TBL] [Abstract][Full Text] [Related]
52. Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study. Ayala R; Fernández RA; García-Gutiérrez V; Alvarez-Larrán A; Osorio S; Sánchez-Pina JM; Carreño-Tarragona G; Álvarez N; Gómez-Casares MT; Duran A; Gorrochategi J; Hernández-Boluda JC; Martínez-López J EJHaem; 2023 May; 4(2):401-409. PubMed ID: 37206258 [TBL] [Abstract][Full Text] [Related]
53. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Maffioli M; Mora B; Ball S; Iurlo A; Elli EM; Finazzi MC; Polverelli N; Rumi E; Caramella M; Carraro MC; D'Adda M; Molteni A; Sissa C; Lunghi F; Vismara A; Ubezio M; Guidetti A; Caberlon S; Anghilieri M; Komrokji R; Cattaneo D; Della Porta MG; Giorgino T; Bertù L; Brociner M; Kuykendall A; Passamonti F Blood Adv; 2022 Mar; 6(6):1855-1864. PubMed ID: 35130339 [TBL] [Abstract][Full Text] [Related]
56. Emerging Treatment Options for Myelofibrosis: Focus on Anemia. Sastow D; Tremblay D Ther Clin Risk Manag; 2023; 19():535-547. PubMed ID: 37404252 [TBL] [Abstract][Full Text] [Related]
57. Standard care and investigational drugs in the treatment of myelofibrosis. Barraco D; Maffioli M; Passamonti F Drugs Context; 2019; 8():212603. PubMed ID: 31645880 [TBL] [Abstract][Full Text] [Related]